Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Company Research
Source: GlobeNewswire
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full data set from open-label extension (OLE) of RECOVER expected in Q1 2025 – CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced positive preliminary topline data for the open-label extension (OLE) portion of the Company’s ongoing Phase 3 RECOVER study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. Administration of brilaroxazine once daily led to robust broad-spectrum efficacy that was sustained over 1 year. Brilaroxazine was ge
Show less
Read more
Impact Snapshot
Event Time:
RVPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVPH alerts
High impacting Reviva Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
RVPH
News
- Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and WarrantsGlobeNewswire
- Reviva Announces Proposed Public OfferingGlobeNewswire
- Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia [Yahoo! Finance]Yahoo! Finance
- Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Reviva Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
RVPH
Earnings
- 11/14/24 - Miss
RVPH
Sec Filings
- 12/20/24 - Form SCHEDULE
- 12/18/24 - Form 8-K
- 12/18/24 - Form 424B5
- RVPH's page on the SEC website